Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPI 287 in Metastatic Melanoma
NCT01340729Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2013
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abeotaxane in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Planned start Sep 2013; status: withdrawn.
02
Drugs
abeotaxane
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01340729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01340729.